Global venture capital firm New Enterprise Associates has promoted Sara Nayeem, M.D., to Partner.
Dr. Nayeem, who joined NEA’s healthcare team in 2009, is focused on investments in biopharma.
She serves on the boards of Mersana, Cydan, Vtesse and Therachon, and as a board observer for Loxo Oncology (LOXO), Ziarco, and Clementia. Dr. Nayeem previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, Proteostasis, and Psyadon.
Prior to joining NEA, she was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions.
Previously, Dr. Nayeem worked as an Investment Banking Analyst at Morgan Stanley.